Clinical Trial Search

Primary: Percentage of Participants With a ≥ 50% Decrease From Baseline in the Frequency of Headache Days — 40.0; 12.0 percentage of participants — p=<0.001

Primary: Number of Disease-free Patients — 5; 12 participants — p=0.0493

Primary: Child Welfare Outcomes: CWS Removal From Birth Parent Home — 7; 16 participants — p==.043

Primary: Count of Participants That Experience Overall Response Following 4 Cycles of the Combination Regimen BBd — 13 Participants

Primary: Incidence of Adverse Events — 465 Events

Primary: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm — 1.7; 1.7 percentage of participants — p=1.00

Primary: Percentage of Participants With Complete Response (CR) or Partial Response [PR, Objective Response Rate (ORR)] — 0.0; 4.8; 0.0 percentage of participants

Primary: Percentage of Participants Who Prefer the Once-monthly Dosing of Ibandronate to the Once-weekly Dosing of Risedronate — 62.42; 21.02 Percentage of participants — p=<0.0001

Primary: Change From Baseline in Parent Rated Social Responsiveness Scale (SRS) Scores During Treatment. — 9.73; 3.18 units on a scale — p=0.0275

Primary: ADHD-RS Total Score — 39.58; 39.75; 20.03; 17.59 units on a scale

Primary: CGM Relative Difference to Laboratory Reference Reported as MARD — 8.5 percent

Primary: HbA1c at 12 Months — 8.73; 9.29 percentage glycated hemoglobin

Primary: Change From Baseline in Appendicular Lean Body Mass (aLBM) at Week 12 — 0.297; 0.741; 1.018; 1.357 percentage change in aLBM (3 limbs) — p=0.527

Primary: Percentage of Participants With Positive Response to TT Vaccine Measured 8 Weeks After TT Vaccine — 23.9; 54.5 percentage of participants

Primary: Latency to Persistent Sleep — -22.7; -39.1; -37.5 minutes